UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients

The international journal of tuberculosis and lung disease, 2011-07, Vol.15 (7), p.949

2011

Volltextzugriff (PDF)

Prospective dose prediction for FXa inhibitor otamixaban (OTAM) using PK/PD simulations accounting for non-dose proportional plasma exposure

Clinical pharmacology and therapeutics, 2005-02, Vol.77 (2), p.P40-P40

2005

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate

Journal of clinical pharmacology, 2021-01, Vol.61 (1), p.90-104

2021

Volltextzugriff (PDF)

Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies

Journal of pharmacokinetics and pharmacodynamics, 2021-08, Vol.48 (4), p.479-494

2021

Volltextzugriff (PDF)

High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma

Journal for immunotherapy of cancer, 2024-03, Vol.12 (3), p.e008325

2024

Volltextzugriff (PDF)

Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis

Advances in therapy, 2021-05, Vol.38 (5), p.2365-2378

2021

Volltextzugriff (PDF)

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

Clinical cancer research, 2020-03, Vol.26 (5), p.1025-1033

2020

Volltextzugriff (PDF)

Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development

Clinical pharmacology and therapeutics, 2024-03, Vol.115 (3), p.422-439

2024

Volltextzugriff (PDF)

P1.22-07 Predictive Biomarkers of Response to REGN5093 to Guide Patient Selection in MET-Altered Advanced Non-small Cell Lung Cancer

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S247

2023

Volltextzugriff (PDF)

1066P Extended-dose cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Primary analysis of phase II results

Annals of oncology, 2021-09, Vol.32, p.S886-S887

2021

Volltextzugriff (PDF)

TRLS-03. A PHASE 1/2 STUDY ASSESSING SAFETY AND PHARMACOKINETICS OF CEMIPLIMAB IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID OR CENTRAL-NERVOUS-SYSTEM TUMORS AND SAFETY AND EFFICACY OF CEMIPLIMAB IN COMBINATION WITH RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA, NEWLY DIAGNOSED HIGH-GRADE GLIOMA, OR RECURRENT HIGH-GRADE GLIOMA

Neuro-oncology (Charlottesville, Va.), 2024-06, Vol.26 (Supplement_4), p.0-0

2024

Volltextzugriff (PDF)

RBTT-09. A PHASE 1 STUDY OF CEMIPLIMAB IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY (R/R) SOLID AND CENTRAL NERVOUS SYSTEM (CNS) TUMORS

Neuro-oncology (Charlottesville, Va.), 2019-11, Vol.21 (Supplement_6), p.vi220-vi220

2019

Volltextzugriff (PDF)

127P Phase I study of fianlimab: A human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced NSCLC

Immuno-oncology technology, 2022-12, Vol.16, p.100239, Article 100239

2022

Volltextzugriff (PDF)

Direct and rapid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease

Clinical pharmacology and therapeutics, 2006-12, Vol.80 (6), p.691-702

2006

Volltextzugriff (PDF)

Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral Therapy

Open forum infectious diseases, 2024-03, Vol.11 (3), p.ofad694-ofad694

2024

Volltextzugriff (PDF)

A first-in-human study of REGN2810, a monoclonal, fully human antibody to programmed death-1 (PD-1), in combination with immunomodulators including hypofractionated radiotherapy (hfRT)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.3024-3024

2016

Volltextzugriff (PDF)

Pharmacokinetics of Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Male Subjects: Pharmacokinetic Model Development for Phase 2/3 Simulation of Exposure

Journal of clinical pharmacology, 2006-01, Vol.46 (1), p.37-44

2006

Volltextzugriff (PDF)

PII-74A model-based approach for evaluating potential contamination of blood samples from a common indwelling catheter and its effects on estimated Actinomycin-D pharmacokinetics

Clinical pharmacology and therapeutics, 2006-02, Vol.79 (2), p.P55-P55

2006

Volltextzugriff (PDF)

1279PPharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice

Antimicrobial Agents and Chemotherapy, 1993-03, Vol.37 (3), p.407-413

1993

Volltextzugriff (PDF)

PII-74

Clinical pharmacology and therapeutics, 2006-02, Vol.79 (2), p.P55-P55

2006

Volltextzugriff (PDF)

Effect of an NK 1 /NK 2 Receptor Antagonist on Airway Responses and Inflammation to Allergen in Asthma

American journal of respiratory and critical care medicine, 2007-03, Vol.175 (5), p.450-457

2007

Volltextzugriff (PDF)

Docetaxel serum protein binding with high affinity to alpha-acid glycoprotein

Investigational new drugs, 1996, Vol.14 (2), p.147-151

1996

Volltextzugriff (PDF)

A single-compartment model cannot describe passive expiration in intubated, paralysed humans

The European respiratory journal, 1991-04, Vol.4 (4), p.458-464

1991

Volltextzugriff (PDF)

Modelling of passive expiration in patients with adult respiratory distress syndrome

The European respiratory journal, 1993-06, Vol.6 (6), p.785-790

1993

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(29)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(13)
Science & Technology
(13)
Humans
(12)
Adult
(9)
Female
(8)
Male
(8)
Pharmacology & Pharmacy
(8)
Middle Aged
(7)
Biological And Medical Sciences
(6)
Medical Sciences
(6)
Adolescent
(4)
Oncology
(4)
Pharmacokinetics
(4)
Aged
(3)
Dose-Response Relationship, Drug
(3)
Immunotherapy
(3)
Models, Biological
(3)
Pharmacology. Drug Treatments
(3)
Respiratory System
(3)
Anesthesia. Intensive Care Medicine. Transfusions. Cell Therapy And Gene Therapy
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients

Prospective dose prediction for FXa inhibitor otamixaban (OTAM) using PK/PD simulations accounting for non-dose proportional plasma exposure

Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate

Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies

High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma

Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development

P1.22-07 Predictive Biomarkers of Response to REGN5093 to Guide Patient Selection in MET-Altered Advanced Non-small Cell Lung Cancer

1066P Extended-dose cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Primary analysis of phase II results

RBTT-09. A PHASE 1 STUDY OF CEMIPLIMAB IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY (R/R) SOLID AND CENTRAL NERVOUS SYSTEM (CNS) TUMORS

127P Phase I study of fianlimab: A human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced NSCLC

Direct and rapid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease

Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral Therapy

A first-in-human study of REGN2810, a monoclonal, fully human antibody to programmed death-1 (PD-1), in combination with immunomodulators including hypofractionated radiotherapy (hfRT)

Pharmacokinetics of Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Male Subjects: Pharmacokinetic Model Development for Phase 2/3 Simulation of Exposure

PII-74A model-based approach for evaluating potential contamination of blood samples from a common indwelling catheter and its effects on estimated Actinomycin-D pharmacokinetics

1279PPharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies

Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice

PII-74

Effect of an NK 1 /NK 2 Receptor Antagonist on Airway Responses and Inflammation to Allergen in Asthma

Docetaxel serum protein binding with high affinity to alpha-acid glycoprotein

A single-compartment model cannot describe passive expiration in intubated, paralysed humans

Modelling of passive expiration in patients with adult respiratory distress syndrome

Suchergebnisse filtern